Haplo-cord HCT offered improved 2-year OS (72.7% vs 61.0%) and DFS (67.0% vs 49.6%) compared with haplo HCT alone.
The European Society for Blood and Marrow Transplantation (EBMT) has released its ninth special report on indications for hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback